JP7324778B2 - セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態 - Google Patents

セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態 Download PDF

Info

Publication number
JP7324778B2
JP7324778B2 JP2020561740A JP2020561740A JP7324778B2 JP 7324778 B2 JP7324778 B2 JP 7324778B2 JP 2020561740 A JP2020561740 A JP 2020561740A JP 2020561740 A JP2020561740 A JP 2020561740A JP 7324778 B2 JP7324778 B2 JP 7324778B2
Authority
JP
Japan
Prior art keywords
compound
salt
theta
degrees
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020561740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523120A (ja
JP2021523120A5 (enExample
Inventor
アンジャリ パンディー，
ジュリアン スコット ノーザン，
フィリップ フェルナンデス，
イン チェン，
ユエリエ ルー，
サミ カラボーニ，
ガス コデルシャ，
Original Assignee
ポートラ ファーマシューティカルズ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポートラ ファーマシューティカルズ， エルエルシー filed Critical ポートラ ファーマシューティカルズ， エルエルシー
Publication of JP2021523120A publication Critical patent/JP2021523120A/ja
Publication of JP2021523120A5 publication Critical patent/JP2021523120A5/ja
Application granted granted Critical
Publication of JP7324778B2 publication Critical patent/JP7324778B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020561740A 2018-05-04 2019-05-03 セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態 Active JP7324778B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862667226P 2018-05-04 2018-05-04
US62/667,226 2018-05-04
PCT/US2019/030717 WO2019213606A2 (en) 2018-05-04 2019-05-03 Solid forms of cerdulatinib

Publications (3)

Publication Number Publication Date
JP2021523120A JP2021523120A (ja) 2021-09-02
JP2021523120A5 JP2021523120A5 (enExample) 2022-05-12
JP7324778B2 true JP7324778B2 (ja) 2023-08-10

Family

ID=66641481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561740A Active JP7324778B2 (ja) 2018-05-04 2019-05-03 セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態

Country Status (5)

Country Link
US (2) US10865198B2 (enExample)
EP (1) EP3788035B1 (enExample)
JP (1) JP7324778B2 (enExample)
TW (1) TW202014412A (enExample)
WO (1) WO2019213606A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10736895B2 (en) 2015-12-04 2020-08-11 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
WO2019213606A2 (en) * 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
TWI805751B (zh) * 2018-05-04 2023-06-21 美商普托拉製藥有限公司 賽度替尼(cerdulatinib)之合成

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518158A (ja) 2008-04-16 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド Ｓｙｋまたはｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド
WO2012045020A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255756A (ja) 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
WO2003037352A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1518855B1 (en) 2002-06-28 2011-10-26 Astellas Pharma Inc. Diaminopyrimidinecarboxa mide derivative
WO2008009458A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8367689B2 (en) 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
WO2010138588A2 (en) 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20120157500A1 (en) 2009-08-24 2012-06-21 Weikang Tao Jak inhibition blocks rna interference associated toxicities
EP2507227B1 (en) 2009-12-01 2014-10-08 Rigel Pharmaceuticals, Inc. Tetrazolones as protein kinase c inhibitors and uses thereof
US9357229B2 (en) 2010-07-28 2016-05-31 Qualcomm Incorporated Coding motion vectors in video coding
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
TW201427664A (zh) 2012-11-02 2014-07-16 Pharmacyclics Inc Ｔｅｃ家族激酶抑制劑佐劑療法
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
JP7258462B2 (ja) 2015-05-29 2023-04-17 ポートラ ファーマシューティカルズ， エルエルシー Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ
JP6833816B2 (ja) 2015-08-12 2021-02-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
US10736895B2 (en) 2015-12-04 2020-08-11 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
CA3098012A1 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Methods for treating lymphoma
TWI805751B (zh) 2018-05-04 2023-06-21 美商普托拉製藥有限公司 賽度替尼(cerdulatinib)之合成
WO2019213606A2 (en) * 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518158A (ja) 2008-04-16 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド Ｓｙｋまたはｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド
WO2012045020A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COFFEY G; ET AL，THE NOVEL KINASE INHIBITOR PRT062070 (CERDULATINIB) DEMONSTRATES EFFICACY IN MODELS OF 以下備考，JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS，2014年10月23日，VOL:351, NR:3，PAGE(S):1 - 34, FIG.(1 - 7,S1 - S4)，http://dx.doi.org/10.1124/jpet.114.218164，AUTOIMMUNITY AND B-CELL CANCER
Jeff Sharman et al.，Ther. Adv. Hematol，2016年，7(3)，pp.157-170，doi: 10.1177/2040620716636542
Journal of Pharmaceutical Sciences，1977年，Vol.66, No.1，p.1-19
川口洋子ら，医薬品と結晶多形，生活工学研究，2002年，Vol.4, No.2，p.310-317
高田則幸，創薬段階における原薬Formスクリーニングと選択，PHARM STAGE，Vol. 6, No. 10，2007年01月15日，pp. 20-25

Also Published As

Publication number Publication date
EP3788035A2 (en) 2021-03-10
WO2019213606A2 (en) 2019-11-07
US20210130330A1 (en) 2021-05-06
TW202014412A (zh) 2020-04-16
WO2019213606A3 (en) 2019-12-05
US10865198B2 (en) 2020-12-15
US11713309B2 (en) 2023-08-01
US20200031804A1 (en) 2020-01-30
JP2021523120A (ja) 2021-09-02
EP3788035B1 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
JP6530792B2 (ja) Ｓｙｋ阻害剤
AU2018201896B2 (en) Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor
JP6756617B2 (ja) Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法
TW200813042A (en) Six membered heteroaromatic inhibitors targeting resistant kinase mutations
CN105452252A (zh) Syk抑制剂的多晶型
CN105324381A (zh) 有关1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1H)-酮的药物制剂、程序、固体形式和使用方法
JP7324778B2 (ja) セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態
TWI711609B (zh) 結晶形式
JP5924453B2 (ja) 二環式含窒素芳香族ヘテロ環アミド化合物
EP3077392B1 (en) Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl - 2-thienyl)-1-phthalazinamine pharmaceutically acceptable salts and uses thereof
JP7430656B2 (ja) Ｃｄｋ４／６活性阻害化合物の結晶形およびその使用
JP2022522395A (ja) 選択的エストロゲン受容体分解剤の新規な塩
JP6986624B2 (ja) Ｓｙｋ阻害剤の多形体
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
HK1225029A1 (en) Syk inhibitors
HK1205430B (en) Salts of an epidermal growth factor receptor kinase inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230727

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230731

R150 Certificate of patent or registration of utility model

Ref document number: 7324778

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150